A Phase I, blinded, randomized, placebo-controlled study to investigate the safety, tolerability, and pharmacokinetics of multiple ascending doses of BIIB132 administered intrathecally to adults with spinocerebellar ataxia 3

Biogen Idec Research Limited0 sites48 target enrollmentMay 5, 2022

Overview

No summary available.

Registry

who.int

Start Date

May 5, 2022

End Date

March 31, 2025

Last Updated

3 years ago

Study Type

Interventional

Sex

All

Sponsor

•1\. Diagnosis of SCA3 with CAG repeats \=60 in ATXN3 gene
•2\. Symptomatic ataxia with a screening Scale for Assessment and Rating of Ataxia (SARA) score 3 to 15 (still ambulatory) and a minimum SARA gait subscore of 1
•3\. Able to ambulate 8 m independently without any assistive device
•4\. Treatment naïve or on a stable dose of symptomatic therapy for a minimum of 4 weeks prior to screening

•1\. Unstable psychiatric illness or untreated major depression within 90 days before screening
•2\. History or screening magnetic resonance imaging (MRI) results show evidence of structural abnormalities that couldcontribute to the participant’s clinical state other than findings typical of SCA3 or any finding that might pose a risk to the participant
•3\. MRI brain findings of prior cerebellar stroke or clinical stroke within 12 months before screening
•4\. History of brain surgery regardless of purpose
•5\. Any contraindications to undergoing brain MRI
•6\. History of, or ongoing, malignant disease, (with the exception of basal cell carcinomas and squamous cell carcinomas that have been completely excised and considered cured at least 12 months prior to screening). Participants with cancers in remission for longer than 5 years may be included
•7\. History of epilepsy or the occurrence of seizures within 3 years prior to screening
•8\. Evidence of untreated/unstable thyroid disease
•9\. Poorly controlled diabetes mellitus
•10\. History of alcohol or substance abuse within the past year prior to screening